Find the right fit for you - faster
Get tailored insights about working at Somaxon in one quick step.
Somaxon Snapshot
If Somaxon Pharmaceuticals is successful in bringing its drugs to market, Las Vegas may see a decline in cigarette-smoking, insomniac gamblers. The vice-busting company's lead product candidate, Silenor, is under development for the treatment of insomnia. A second product, nalmefene, is being developed to treat compulsive disorders such as gambling, kleptomania, pyromania, and compulsive spending; the company is also looking into its effectiveness as a smoking cessation drug. Somaxon is focused on developing and bringing to market treatments for psychological and neurological disorders.
